Clinical use of cefuroxime in paediatric community-acquired pneumonia

Paediatric Drugs

Volumn 2, Issue 5, 2000, Pages 331-343

  Olivier, C ^a  

^a HÔPITAL LOUIS MOURIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE DERIVATIVE; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; CEFACLOR; CEFUROXIME; CEFUROXIME AXETIL; CHLORAMPHENICOL DERIVATIVE; DICLOXACILLIN; DOXYCYCLINE; MACROLIDE; PROCAINE PENICILLIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC THERAPY; CHILD; CHLAMYDIA; CLINICAL PROTOCOL; COUGHING; DISEASE SEVERITY; DRUG EFFICACY; DRUG TOLERABILITY; FEVER; HUMAN; LEGIONELLA; LUNG PARENCHYMA; MINIMUM INHIBITORY CONCENTRATION; MYCOPLASMA; PLEURA EFFUSION; PNEUMONIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; RESPIRATORY DISTRESS; REVIEW; TACHYPNEA; TREATMENT OUTCOME;

EID: 0033814997     PISSN: 11745878     EISSN: None     Source Type: Journal    
DOI: 10.2165/00128072-200002050-00001     Document Type: Review

References (75)

1. Pneumonia: Antimicrobial therapy for infants and children
2. Acute lower respiratory tract infections
3. Aetiology of pneumonia in children in Goroka Hospital Papua New Guinea
4. WHO guidelines on detecting pneumonia in children
5. Management of complicated parapneumonic effusions
6. Antibiotic therapy of childhood pneumonia
7. Increasing role of resistance in LRTIs
8. The child with pneumonia: Diagnostic and therapeutic considerations
9. Bacterial pneumonias
10. Reliability of the chest radiograph in the diagnosis of lower respiratory infections in young children
11. Atypical pneumonias in children
12. Diagnostic radiology of the respiratory tract
13. Comparison of procalcitonin with C-reactive protein, interleukin 6 and interferon-alpha for differentiation of bacterial vs viral infections
14. Problems in determining the etiology of community-acquired childhood pneumonia
15. Erythromycin sedimentation rate, white blood cell count and serum C-reactive protein in assessing etiologic diagnosis of acute lower respiratory infections in children
16. Comparison of radiological findings and microbial aetiology of childhood pneumonia
17. Lung tap in childhood: Bacteria, viruses and mycoplasmas in acute lower respiratory tract infections
18. Diagnosis of acute bacterial pneumonia in Nigerian children
19. Mycoplasma pneumoniae and Chlamydia pneumoniae in community acquired pneumonia in children: Comparative safety and efficacy of clarithromycin and erythromycin suspensions
20. Safety and efficacy of azithromycin in the treatment of community acquired pneumonia in children
21. Microbiology of acute paediatric infections
22. Etiology and response to antibiotic therapy of community-acquired pneumonia in French children
23. Branhamella catarrhalis as an indirect pathogen
24. Staphylococci
25. Prospective study on the etiology of community-acquired pneumonia in children and adults in Spain
26. Counter immunoelectrophoresis and latex particle agglutination in the etiologic diagnosis of presumed bacterial penumonia in pediatric patients
27. Etiology of community-acquired pneumonia in children based on antibody responses to bacterial and viral antigens
28. The causes of hospital-treated acute lower respiratory tract infection in children
29. Pneumonia in childhood: Etiology and response to antimicrobial therapy
30. Cefuroxime efficacy in pneumonia: Sequential short-course iv/oral suspension therapy
31. Trends in antimicrobial susceptibility of bacterial pathogens of the respiratory tract
32. Antimicrobial resistance in Streptococcus pneumoniae: An overview
33. Resistant pneumococci: Protecting patients through judicious use of antibiotics
34. Acute otitis media: Management and surveillance in an era of pneumococcal resistance: A report from the Drug-resistant Streptococcus pneumoniae Therapeutic Working Group
35. Toward an integrated program for patient care in pediatric infections
36. Community-acquired pneumonia in adults: Guidelines for management
37. Guidelines for management of adult community-acquired lower respiratory tract infections
38. Clinical relevance of intracellular and extracellular concentrations of macrolides
39. Relevance of pharmacokinetics and pharmacodynamics in the selection of antibiotics for respiratory tract infections
40. Cefuroxime axetil: A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy
41. Plasmid mediated beta-lactamases of Gram-negative bacteria: Properties and distribution
42. Pharmacology of cefuroxime as the 1-acetoxyethyl ester in volunteers
43. The absolute bioavailability of oral cefuroxime axetil in male and female volunteers after fasting and after food
44. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins
45. The pharmacokinetics of cefuroxime in man in relation to its antibacterial activity
46. Pharmacokinetics of cefuroxime axetil suspension in infants and children
47. Traitement des pneumonies bacteriennes par le cefuroxime-axetil; valeur predictive de la mesure de la sensibilite in vitro
48. Cefuroxime: A review of its antibacterial activity, pharmacological properties and therapeutic use
49. Parapneumonic pleural effusion and empyema in children: Review of a 19-year experience, 1962-1980
50. Paediatric parapneumonic effusions: A review of 16 cases
51. Parapneumonic effusions
52. The incidence and clinical correlates of parapneumonic effusions in pneumococcal pneumonia
53. Strategies for early discharge of the hospitalized patient with community-acquired pneumonia
54. Sequential therapy with cefuroxime followed by cefuroxime axetil in community-acquired pneumonia
55. Cefuroxime and cefuroxime axetil versus amoxycillin plus clavulanic acid in the treatment of lower respiratory tract infections
56. Parenteral cefuroxime followed by cefuroxime axetil in the treatment of children with community acquired pneumonia
57. Sequential therapy with cefuroxime followed by cefuroxime axetil in community-acquired lower respiratory tract infections in children
58. A multicenter trial comparing the efficacy and safety of cefuroxime axetil and cefaclor in pneumonia of adults
59. Comparison of oral cefuroxime axetil and oral amoxycillin/clavulanate in the treatment of community-acquired pneumonia
60. Comparison of cefuroxime axetil and cefaclor for patients with lower respiratory tract infections presenting to a rural family practice clinic
61. Blinded comparison of cefuroxime to cefaclor for lower respiratory tract infections
62. Efficacy and safety of cefprozil versus other beta-lactam antibiotics in the treatment of lower respiratory tract infections
63. Evaluation of nasopharyngeal cultures for bacteriologic assessment of acute otitis media in children
64. Placental transfer of cefuroxime
65. Cefuroxime in treatment of neonates
66. Comparison of cefuroxime axetil, cefaclor, and amoxycillin-clavulanate potassium suspensions in acute otitis media in infants and children
67. Clinical comparison of cefuroxime axetil suspension and amoxycillin/clavulanate suspension in the treatment of pediatric patients with acute otitis media with effusion
68. Comparison of cefuroxime axetil and amoxycillin-clavulanate suspensions in the treatment of acute otitis media with effusion in children